Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2014; 139(49): 2491-2493
DOI: 10.1055/s-0034-1387393
DOI: 10.1055/s-0034-1387393
Angiologie | Commentary
Angiologie
Blutungskomplikationen unter oraler Antikoagulation
Bleeding complications under oral anticoagulationFurther Information
Publication History
Publication Date:
06 November 2014 (online)
-
Vitamin-K-Antagonisten (VKA): Die Häufigkeit schwerer Blutungen unter Vitamin-K-Antagonisten wird im klinischen Alltag oft unterschätzt.
-
Nicht-VKA-basierte orale Antikoagulanzien (NOAK): Sie verringern das Blutungsrisiko in Studien und im klinischen Alltag.
-
Schwere Antikoagulanzienblutung: Die Prognose ist unter NOAK deutlich besser als unter VKA.
-
Blutungen unter oraler Antikoagulation: Das Management ist abhängig von Lokalisation und Schwere der Blutung. Verschiedene Antidots befinden sich in klinischer Entwicklung.
-
Literatur
- 1 Beyer-Westendorf J, Forster K, Pannach S et al. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. Blood 2014;
- 2 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99
- 3 Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817
- 4 Gitter MJ, Jaeger TM, Petterson TM et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733
- 5 Gomes T, Mamdani MM, Holbrook AM et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj 2013; 185: E121-127
- 6 Halbritter K, Beyer-Westendorf J, Nowotny J et al. Hospitalization for Vitamin-K-Antagonist-related bleeding – treatment patterns and outcome. J Thromb Haemost 2013; 11: 651-659
- 7 Hylek EM, Held C, Alexander JH et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63: 2141-2147
- 8 Koscielny J, Beyer-Westendorf J, von Heymann C et al. [Risk of bleeding and haemorrhagic complication with rivaroxaban – periprocedural management of haemostasis]. Hamostaseologie 2012; 32: 287-293
- 9 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900
- 10 Majeed A, Hwang HG, Connolly SJ et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332
- 11 Piccini JP, Garg J, Patel MR et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014;
- 12 Steffensen FH, Kristensen K, Ejlersen E et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497-503
- 13 Steiner T, Bohm M, Dichgans M et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412
- 14 Willey VJ, Bullano MF, Hauch O et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-1159